DiamiR
Healthcare Services · New Jersey, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
116 Village Blvd Ste 200, Princeton, New...Phone Number
(609) 951-2222Website
www.diamirbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
2
2
1
1
About DiamiR
DiamiR is a privately held molecular diagnostics company focused on developing minimally invasive tests for detection and monitoring of pathology based on quantitative analysis of organ-enriched microRNA signatures in plasma for screening, patient stratification, as well as disease progression and treatment monitoring. DiamiR collaborates with leading academic centers, disease foundations, and biopharma companies.Explore more
DiamiR Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is DiamiR your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once DiamiR has new funding data
DiamiR, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if DiamiR is spiking on competitors!
Check if DiamiR has recently received funding, and reach out quickly before it becomes old news!
Click to see if DiamiR had a recent Job posting/layoffs
Earning: See what the market has to say on DiamiR recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at DiamiR
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when DiamiR launches new products
Recommended Actions
Find VP level buyers at DiamiR
Find more new buyers
Compare Similar Companies to DiamiR
Compare insights from companies similar to DiamiR, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
DiamiR is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
DiamiR is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about DiamiR.
DiamiR financials insights
Gather financial insights about DiamiR, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Grant
$345K
DiamiR Tech Stack
A closer look at the technologies used by DiamiR
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Project
Product Management, Intellectual Property, Legal Affairs, Medical Research
New Hire
Executive Move
New Hire
Executive Move
DiamiR News & Media
As part of the planned merger with DiamiR Biosciences, Aptorum Group will expand its board and management team with seasoned executives
NEW YORK, NY, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announces the addition of Dr. Laura A. Philips to its board of directors as an independent director at closing of the merger with DiamiR Biosciences Corp.DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR’s APOE Genotyping Test
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that DiamiR received a Clinical Laboratory Evaluation Program (CLEP) Test Approval for its APOE Genotyping testAptorum Group Limited Regains Compliance with NASDAQ’s Minimum Bid Price Requirement
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, today announced that it received formal written notification from The Nasdaq Stock Market, LLC (“Nasdaq”) confirming that the company has regained compliance with Nasdaq’s minimum bid price requirement.Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology and infectious diseases, and DiamiR Biosciences (“DiamiR”), a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA licensed, CAP accredited clinical laboratory in New Haven, CT, today announced that they have entered into a d
Read more news
Top Healthcare Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding DiamiR
Sign Up For FreeTo access detailed company insights
DiamiR is a privately held molecular diagnostics company focused on developing minimally invasive tests for detection and monitoring of pathology based on quantitative analysis of organ-enriched microRNA signatures in plasma for screening, patient stratification, as well as disease progression and treatment monitoring. DiamiR collaborates with lead... Read More
